Return of Rights. Notwithstanding the above,
Return of Rights. If Licensee fails to begin to develop specific plans for applications for particular Crops, uses or territories subject to this Addendum within three years of the Addendum Effective Date, Demegen may propose a specific plan for such and bring to Licensee a suitable party ready, willing and able to implement such plan. If Licensee does not reach an agreement with such party for the particular Crop(s) involved, or develop and initiate a suitable alternative plan for development internally or with another party, then Demegen may request that Licensee's rights to Licensed Patents and Demegen Technology in said area(s) be returned to Demegen so as to permit Demegen to pursue said plan. Licensee shall not unreasonably refuse to return said rights to Demegen, provided, however, that Licensee will retain a non exclusive license to Licensed Patents and Licensed Technology in said area(s) unless the parties negotiate otherwise. As long as Licensee is not in breach of any material term of this agreement, it will not be compelled under this Article IX to turn over to Demegen any of Licensee's rights in Joint Inventions without compensation. If the parties are unable to agree on the application of this provision with respect to a particular Crop application, or the terms of a license for such application, then the matter will be submitted to arbitration in accordance with the provisions of Paragraph J of Article XVIII of the Agreement.
Return of Rights. (a) In the event that, absent a determination by Novartis that is not commercially reasonable to do so and receipt of a notification to this effect pursuant to Section 6.2(c), Novartis decides permanently to not to seek Regulatory Approval for Products in a country in the Territory outside of the Key Countries or to not Commercialize Products (or not to continue to Commercialize Products) in any country in the Territory outside of the Key Countries, it will provide GW with written notice of such decision and the provisions of Section 6.4(d) shall apply with respect to that country.
Return of Rights. In the event that a Triggering Event under the Rights Plan occurs during the Exercise Period but this Warrant is never exercised during the Exercise Period, then the Holder's Rights under the Rights Plan granted pursuant to Section 18.1 shall expire on the Expiration Date. In the event a portion, but less than all, of this Warrant is exercised during the Exercise Period, then the Holder's prorated share of the Rights corresponding to the unexercised portion of this Warrant shall so expire.
Return of Rights. Except as reasonably necessary for surviving rights or obligations under this Article 15, (i) all of PARI’s and Transave’s license rights under Articles 3.1 and 4 shall terminate, and (ii) each of Transave and PARI shall promptly return all Confidential Information then in possession in accordance with Section 11.4 of this Agreement.
Return of Rights. 2.1 BIOSANTE hereby returns its rights granted under the Agreement as part of the license (including without limitation rights to Develop, apply and receive Approval as applicant, Market, use and sell) to ANTARES with respect to:
Return of Rights. In the event of termination of this Agreement by any party hereto pursuant to subparagraph (a), (b), (c) or (d) of Section 2.1 hereof, and unless each of the Company, JPMorgan, Telia, the WP Entities and the Committee otherwise agree following consultation among such parties (such consultation not to exceed five Business Days following the date of termination of this Agreement), the parties hereto agree that the rights of the parties hereto shall be returned following such five-Business Day consultation period to the same as prior to the entering into of this Agreement, despite one or more of the Restructuring Steps having been completed. For the avoidance of doubt, in the event of termination pursuant to subparagraphs (a), (b), (c) or
Return of Rights. If Sanofi elects, pursuant to this Section 13.4, to return the rights to the Product to MannKind:
Return of Rights. Except as reasonably necessary for each Party’s surviving rights or obligations under this Article 11, in the event of any termination (but not expiration) of this Agreement other than due to MacroMed’s material breach hereof, (a) all of Diatos’s license rights with respect to the Licensed Technology shall terminate, and (b) each Party shall promptly destroy, or if requested by the other Party within forty-five (45) days after such termination return, all Confidential Information of the other Party then in such Party’s possession or control; provided that each Party also may retain one (1) copy of such Confidential Information in its legal files for purposes of determining the scope of its rights and obligations hereunder; provided that such copy shall remain subject to the non-use and non-disclosure provisions hereof.
Return of Rights. In the event of termination of this Agreement by any party hereto pursuant to subparagraph (a), (b), (c) or (d) of Section 2.1 hereof, and unless each of the Company, JPMorgan, Telia, the WP Entities and the Committee otherwise agree following consultation among such parties (such consultation not to exceed five Business Days following the date of termination of this Agreement), the parties hereto agree that the rights of the parties hereto shall be returned following such five-Business Day consultation period to the same as prior to the entering into of this Agreement, despite one or more of the Restructuring Steps having been completed. For the avoidance of doubt, in the event of termination pursuant to subparagraphs (a), (b), (c) or (d) of Section 2.1, (i) the Consenting Noteholders shall maintain any rights and remedies available to them under the Indentures, applicable Law or otherwise with respect to any Default (as defined in the Indentures) that may have occurred at any time prior to such an event and which Default has not been waived or otherwise cured; and (ii) JPMorgan shall maintain any rights and remedies available to it under the JPMorgan Swaps, applicable law or otherwise.
